Giant Cell Arteritis Diagnosis and Management
Clinical Presentation
- The American College of Rheumatology suggests that giant cell arteritis presents with a constellation of cranial, systemic, and vascular manifestations that require immediate recognition to prevent irreversible vision loss, with new-onset headache being the most common presenting symptom 1
- Jaw claudication has a positive likelihood ratio of 4.90, making it one of the strongest clinical predictors, and scalp tenderness occurs frequently with a positive LR of 3.14 3
- Temporal artery abnormalities, including thickening, tenderness, and loss of pulse, are common manifestations with positive LRs of 4.70, 3.14, and 3.25, respectively 3
- Vision loss occurs in 14-18% of patients and represents the most feared complication, with polymyalgia rheumatica symptoms and constitutional symptoms also being common 1
- Limb claudication has the highest positive LR of 6.01, and ESR >100 mm/h has a positive LR of 3.11, while ESR >40 mm/h is present in >95% of cases 3
Laboratory Findings
- Elevated ESR and CRP are common laboratory findings, with ESR >40 mm/h being present in >95% of cases and CRP ≥2.5 mg/dL being elevated in most cases, and platelet count >400 × 10³/μL has a positive LR of 3.75 3, 2
- The presence of these laboratory findings can guide diagnostic decisions, but no single feature is sufficient alone to confirm or exclude GCA 3
Treatment Approach
- The American College of Rheumatology recommends that all patients with suspected GCA must receive empiric high-dose glucocorticoids immediately, with high-dose oral prednisone 40-60 mg daily being the cornerstone of initial treatment 2, 4
- Low-dose aspirin 75-150 mg daily should be given to all GCA patients to reduce cardiovascular and cerebrovascular events, and tocilizumab should be considered as adjunctive therapy to reduce glucocorticoid requirements and flare rates 4
- Clinical monitoring with ESR and CRP should guide treatment decisions and steroid tapering, and periodic imaging may be necessary for patients with known large-vessel involvement to assess complications 4